SGLT2 inhibitors are medicines that help people with heart failure (HF) by lowering the chances of hospital visits and heart problems. They work by blocking a part of the kidney called the sodium-glucose cotransporter 2 (SGLT2). This study looks at how genetic differences, or polymorphisms, in a gene called SLC5A2 might change how well SGLT2 inhibitors work in people with heart failure.
To join the study, you must be a heart failure patient and a candidate for SGLT2 treatment. Pregnant women or those with recent heart surgeries cannot join. The study aims to find out which genetic changes help SGLT2 inhibitors work better.
- Study requires heart failure patients willing to sign consent.
- Genetic testing will be done to see how well SGLT2 drugs work.
- Participants should not have significant heart surgeries recently.
How understandable was the trial content above?
Hard to understand
Easy to understand